CNDO-109-AANK

· Coronado Biosciences, Inc.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for CNDO-109-AANK, covering 2017-06-29 to 2017-06-29. Get the full timeline:

Most recent: Clinical Trial Update: CNDO-109-AANK for AML in First Complete Remission (CR1) [Phase 1, Phase 2]